RhumbLine Advisers’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
RhumbLine Advisers's DFTX Position: Q3 2026 in Review
RhumbLine Advisers increased its Definium Therapeutics (DFTX) stake by 1.6% in Q3 2026, buying an estimated $104K and bringing the position to 160,569 shares worth $6.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1312.
RhumbLine Advisers first reported a position in DFTX in Q2 2021 and has held it in 14 quarters since. The position peaked at $7.44M in Q2 2026. 349 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.
- RhumbLine Advisers held 160,569 shares of Definium Therapeutics worth $6.11M as of Q3 2026.
- RhumbLine Advisers bought 2,473 Definium Therapeutics shares in Q3 2026, an estimated $104K.
- Definium Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1312 holding.
- RhumbLine Advisers first reported a position in Definium Therapeutics in Q2 2021 and has held it in 14 quarters since.
- RhumbLine Advisers's Definium Therapeutics position peaked at $7.44M in Q2 2026.
- 349 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.